Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro.

September 18, 2018

Zhang et al. • 2008 • Zhonghua Wai Ke Za Zhi. 2006;44(6):382-5.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002018-09-18 00:00:00Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro.

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.

September 18, 2018

Nanda et al. • 2016 • Springerplus. 2016;5(1):947.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002018-09-18 00:00:00A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

September 18, 2018

Baker et al. • 2015 • Cancer Manag Res. 2015;7:361-8.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002018-09-18 00:00:00Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer

September 18, 2018

Nanda et al. • 2013 • Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-21.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002018-09-18 00:00:00A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer

Glucocorticoid receptors in the prefrontal cortex regulate dopamine efflux to stress via descending glutamatergic feedback to the ventral tegmental area.

September 18, 2018

Butts KA, Phillips AG. • 2013 • Int J Neuropsychopharmacol. 2013;16(8):1799-807.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002024-03-12 00:37:53Glucocorticoid receptors in the prefrontal cortex regulate dopamine efflux to stress via descending glutamatergic feedback to the ventral tegmental area.

A mixed glucocorticoid/mineralocorticoid receptor modulator dampens endocrine and hippocampal stress responsivity in male rats.

September 18, 2018

Nguyen et al. • 2017 • Physiol Behav. 2017;178:82-92.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002024-03-12 00:37:53A mixed glucocorticoid/mineralocorticoid receptor modulator dampens endocrine and hippocampal stress responsivity in male rats.

The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.

September 18, 2018

Solomon et al. • 2014 • Horm Behav. 2014;65(4):363-71.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002024-03-12 00:37:53The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.

Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.

September 18, 2018

Zalachoras et al. • 2013 • Proc Natl Acad Sci U S A. 2013;110(19):7910-7915.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002024-03-12 00:37:53Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.

Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

September 18, 2018

Lenze et al. • 2014 • Int J Geriatr Psychiatry. 2014;29(9):962-9.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002024-03-12 00:37:54Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486).

September 18, 2018

van der Lely et al. • 1991 • Ann Intern Med. 1991;114(2):143-4.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-18 00:00:002024-03-12 00:37:54Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486).
Page 10 of 13«‹89101112›»

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top